Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Colloidal precipitates01:09

Colloidal precipitates

The high insolubility of some precipitates can result in an unfavorable relative supersaturation. This can lead to colloidal particles with a large surface-to-mass ratio, where adsorption is promoted. For instance, in the precipitation of silver chloride, silver ions are adsorbed on the surface of the colloidal particles, forming a primary layer. This layer attracts ions of opposite charge (such as nitrate ions), forming a diffuse secondary layer of adsorbed ions. This electric double layer...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Valent Rhodium and Iridium Assemblies Directed by Uracilate and Guaninate Linkers.

Inorganic chemistry·2026
Same author

Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

International journal of clinical oncology·2026
Same author

Breaking the Mold: Electrophilic Hydrophosphanation Emerges.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Targeting von Willebrand factor selectively under inflammatory conditions.

bioRxiv : the preprint server for biology·2026
Same author

Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma.

Cancers·2026
Same author

Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity.

Leukemia·2026
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
Same journal

Abstracts of the 39th International Congress of the ISBT, Kuala Lumpur, Malaysia, 20-24 June 2026.

Vox sanguinis·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Factors associated with aggregate formation in cold-stored platelets.

Samantha Huang1, Yuko Mishima1, S Lawrence Bailey1

  • 1Bloodworks Northwest Research Institute, Seattle, Washington, USA.

Vox Sanguinis
|May 25, 2026
PubMed
Summary
This summary is machine-generated.

Platelet aggregates in cold-stored platelets are linked to donor factors like sex, age, and blood type. Understanding these associations may help improve platelet storage and reduce waste.

Keywords:
cardiothoracic surgerycold‐stored plateletsplatelet storageplatelet transfusion

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Experiment Videos

Last Updated: May 26, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Area of Science:

  • Hematology
  • Transfusion Medicine
  • Biotechnology

Background:

  • Cold-stored platelets (CSPs) can form aggregates, reducing their usability.
  • The underlying causes and prevention strategies for CSP aggregation remain unclear.
  • This study investigates factors influencing aggregate formation in CSPs stored for up to 14 days.

Purpose of the Study:

  • To identify donor-related factors associated with aggregate formation in CSPs.
  • To explore the role of thrombosis and inflammation markers in CSP aggregation.
  • To assess the impact of von Willebrand factor (VWF) on platelet aggregation during storage.

Main Methods:

  • Retrospective analysis of aggregate rates in 79 unique donors' CSPs.
  • Evaluation of donor sex, age, and ABO blood group.
  • Enzyme-linked immunosorbent assay for thrombosis/inflammation markers and VWF levels.
  • In vitro studies using VWF-deficient mouse platelets and human platelets with VWF/caplacizumab.

Main Results:

  • 57% of CSP units formed aggregates.
  • Aggregates were associated with lower soluble thrombomodulin and higher VWF levels.
  • Female donors and donors with ABO type A showed higher aggregation rates.
  • Older donor cohorts had fewer aggregates; VWF manipulation had inconsistent effects.

Conclusions:

  • Donor sex, age, ABO type, and thrombomodulin levels are significantly associated with CSP aggregate formation.
  • These findings highlight donor characteristics as key factors in platelet storage quality.
  • Further research may lead to strategies for minimizing platelet aggregation and improving transfusion safety.